{"id":"W4281719812","doi":"10.1016/j.currproblcancer.2022.100875","title":"Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence","year":2022,"lang":"en","type":"review","venue":"Current Problems in Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"Ipsen; Clovis Oncology; Roche; Merck; Janssen Pharmaceuticals; Bayer; AstraZeneca","keywords":"Pembrolizumab; Medicine; Sunitinib; Lenvatinib; Internal medicine; Oncology; Axitinib; Renal cell carcinoma; Nivolumab; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006410806,0.002007208,0.011225,0.00200009,0.0003936157,0.00232139,0.001501001,0.001895226,0.005861438],"category_scores_gemma":[0.01228014,0.001037561,0.02295682,0.003191668,0.0004492174,0.001476699,0.001026363,0.002285024,0.0004670274],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001759122,"about_ca_system_score_gemma":0.00219011,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006220629,"about_ca_topic_score_gemma":0.01988817,"domain_scores_codex":[0.996777,0.001560383,0.0007289943,0.0004450144,0.0003253707,0.0001633317],"domain_scores_gemma":[0.9949556,0.003512462,0.0009045649,0.0001911813,0.0003226666,0.000113516],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.004593933,0.00003917066,0.003476625,0.2866349,0.6717137,0.0001296625,0.00006365032,0.0005107301,0.0004572516,0.0002180106,0.001810986,0.03035141],"study_design_scores_gemma":[0.001528091,0.0002250057,0.003313321,0.01602924,0.9741966,0.00007116879,0.00002949843,0.0001290918,0.00008702477,0.0003010671,0.004068656,0.00002124089],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.002562213,0.9958695,0.0003132478,0.0002393776,0.0001636168,0.00007925887,0.0003832453,0.00001714566,0.0003723863],"genre_scores_gemma":[0.1407698,0.8534996,0.001602501,0.002093157,0.0003667042,0.0002120622,0.0007913369,0.00003200263,0.0006328751],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.011225,"threshold_uncertainty_score":0.03390402,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.5262294098724305,"score_gpt":0.447444856489776,"score_spread":0.0787845533826545,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}